DEUCRAVACITINIB - Generic Drug Details

What are the generic sources for deucravacitinib and what is the scope of freedom to operate?

Deucravacitinib is the generic ingredient in one branded drug marketed by Bristol and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Deucravacitinib has seventy patent family members in thirty-eight countries.

One supplier is listed for this compound.

Summary for DEUCRAVACITINIB

International Patents:	70
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	31
Clinical Trials:	42
What excipients (inactive ingredients) are in DEUCRAVACITINIB?	DEUCRAVACITINIB excipients list
DailyMed Link:	DEUCRAVACITINIB at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for DEUCRAVACITINIB

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for DEUCRAVACITINIB

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	PHASE2
Takeda	PHASE3
Chinese SLE Treatment And Research Group	PHASE4

See all DEUCRAVACITINIB clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for DEUCRAVACITINIB

L04AA	Selective immunosuppressants
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

L04AF	Janus-associated kinase (JAK) inhibitors
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for DEUCRAVACITINIB

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol	SOTYKTU	deucravacitinib	TABLET;ORAL	214958-001	Sep 9, 2022		RX	Yes	Yes			Y	Y
Bristol	SOTYKTU	deucravacitinib	TABLET;ORAL	214958-001	Sep 9, 2022		RX	Yes	Yes
Bristol	SOTYKTU	deucravacitinib	TABLET;ORAL	214958-001	Sep 9, 2022		RX	Yes	Yes			Y	Y
Bristol	SOTYKTU	deucravacitinib	TABLET;ORAL	214958-001	Sep 9, 2022		RX	Yes	Yes

EU/EMA Drug Approvals for DEUCRAVACITINIB

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Bristol-Myers Squibb Pharma EEIG	Sotyktu	deucravacitinib	EMEA/H/C/005755Treatment of moderate-to-severe plaque psoriasis in adults.	Authorised	no	no	no	2023-03-24

International Patents for DEUCRAVACITINIB

Country	Patent Number	Title	Estimated Expiration
Hungary	S2300025
Hong Kong	1215255
Hungary	S2300025
Cyprus	1125220
Norway	2023032

Supplementary Protection Certificates for DEUCRAVACITINIB

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2922846	C202330032	Spain		PRODUCT NAME: DEUCRAVACITINIB O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/23/1718; DATE OF AUTHORISATION: 20230324; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1718; DATE OF FIRST AUTHORISATION IN EEA: 20230324
2922846	PA2023523	Lithuania		PRODUCT NAME: DEUKRAVACITINIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1718 20230324
2922846	LUC00313	Luxembourg		PRODUCT NAME: DEUCRAVACITINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1718 20230327
2922846	PA2023523,C2922846	Lithuania		PRODUCT NAME: DEUKRAVACITINIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1718 20230324
2922846	23C1030	France		PRODUCT NAME: DEUCRAVACITINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/23/1718 20230327

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: Deucravacitinib

Last updated: July 28, 2025

---

Introduction

Deucravacitinib, marketed as Sotyktu®, represents a pioneering oral biologic—a selective TYK2 inhibitor—developed by Bristol-Myers Squibb (BMS). Approved by the FDA in September 2022 for moderate to severe plaque psoriasis, deucravacitinib's emergence signifies a potential paradigm shift within immune-modulating therapies. This article explores the extensive market dynamics, competitive landscape, regulatory pathways, revenue projections, and strategic factors shaping its financial trajectory.

---

Market Overview and Therapeutic Context

Deucravacitinib addresses unmet needs in autoimmune disease management, particularly for psoriasis, where biologics and systemic therapies dominate. As of 2022, global psoriasis treatment revenues approach USD 12 billion, with biologics constituting a substantial share due to their efficacy, albeit with high costs and administration challenges (1). The ideal profile of deucravacitinib—oral administration, high selectivity, and improved safety—positions it to expand its market potential, not only in psoriasis but also in other indications like psoriatic arthritis and systemic lupus erythematosus (SLE). The drug’s profile is aligned with current shifts favoring oral biologics over traditional injectables.

---

Market Dynamics: Drivers and Barriers

Drivers

1. Efficacy and Safety Profile
Deucravacitinib exhibits high selectivity for TYK2, reducing off-target effects seen in broader Janus kinase (JAK) inhibitors. Clinical trials demonstrate comparable or superior efficacy with fewer adverse events (2), encouraging physician adoption and patient adherence.

2. Patient Preference and Convenience
Oral therapy offers significant advantages over injectable biologics, increasing acceptance among patients and reducing administration costs. This aligns with the broader trend towards self-administered therapies.

3. Expanding Therapeutic Indications
Beyond psoriasis, deucravacitinib’s mechanism targets pathways implicated in several immune-mediated diseases, offering expansion into psoriatic arthritis, lupus, and inflammatory bowel disease. Multi-indication strategies can significantly enhance revenue streams.

4. Strategic Market Entry by Major Players
BMS’s early regulatory approval secures a first-mover advantage in oral TYK2 inhibitors, potentially capturing substantial market share before competition intensifies.

Barriers

1. Competition from Established Biologics and Newer Oral Agents
Existing treatments—such as Stelara®, Cosentyx®, and Humira®—boast decades of market penetration. Competitive pressure from emerging oral JKAs or biosimilars may impede rapid growth.

2. Cost and Reimbursement Challenges
Pricing strategies will influence adoption. Although deucravacitinib may command premium pricing, reimbursement policies and cost-effectiveness evaluations could temper growth (3).

3. Market Penetration and Physician Adoption
Physicians tend to favor proven biologics with long-term safety data. Convincing clinicians to shift prescribing habits requires extensive post-market data, which may delay peak adoption.

4. Regulatory and Safety Concerns
Long-term safety data are essential. Potential safety signals or adverse effects may moderate prescribing patterns.

---

Regulatory and Pricing Strategies

BMS’s rapid approval of deucravacitinib underscores confidence in its safety and efficacy profile. Continued regulatory endorsements across different regions can catalyze global expansion. Pricing strategies likely will position deucravacitinib as a premium yet cost-effective alternative, leveraging its oral convenience and safety advantages.

In markets like the US and Europe, pricing expectations will balance considering costs, payer negotiations, and market acceptance. The drug’s placement within formularies and insurance plans will significantly influence revenue trajectories.

---

Revenue Projections and Financial Outlook

Initial Launch Phase (2022–2024)

Post-approval, BMS forecasts initial revenues in the low hundreds of millions USD, driven by early uptake in psoriasis patients switching from injectable biologics. Uptake depends on the speed of physician adoption, patient awareness, and payer coverage.

Mid-term Expansion (2025–2028)

As clinical evidence broadens, deucravacitinib can capture a larger share of the psoriasis market—estimated to approach USD 4–6 billion globally by 2028—assuming steady growth in prescription volume. Expansion into psoriatic arthritis and lupus further amplifies revenue streams, potentially adding an incremental USD 1–2 billion annually (4).

Long-term Outlook (2029 and beyond)

Global market penetration, especially in emerging markets, could drive revenues upward of USD 8–10 billion globally. Differentiation based on efficacy, safety, and convenience will underpin sustained growth. Continued post-market studies and label expansions can solidify its positioning in other immune-mediated conditions.

In addition, patent exclusivity extending through the 2030s, coupled with minimal biosimilar threats (given its novel mechanism), suggests a favorable long-term financial outlook. Strategic collaborations, licensing, and line extensions could further enhance profitability.

---

Competitive Landscape and Strategic Positioning

The TYK2 inhibition space is relatively nascent but rapidly evolving. Clinical pipeline drugs from Pfizer, AbbVie, and other biotech players are exploring similar pathways (5). Yet, deucravacitinib’s distinctive selectivity profile gives it a competitive edge.

Key Differentiators:

• Oral administration
• High selectivity with tolerable safety profile
• Broad potential across multiple autoimmune diseases

Challenges:

• Surmounting entrenched biologics
• Establishing long-term safety success
• Navigating pricing and reimbursement dynamics

---

Concluding Remarks

Deucravacitinib’s journey from regulatory approval to maximizing market share hinges on multiple factors—from clinical acceptance and competitive positioning to payer strategies and geographic expansion. As an innovative oral TYK2 inhibitor, its potential to redefine immune therapy markets is considerable, with projected revenues scaling into the multi-billion dollar range over the coming decade.

---

Key Takeaways

• Deucravacitinib's unique selectivity and oral formulation position it favorably within autoimmune therapies, especially for psoriasis.
• Market growth is driven by physician acceptance, expanding indications, and patient preference for oral treatments.
• Competition remains fierce from established biologics and emerging oral alternatives, requiring strategic differentiation.
• Revenue projections suggest a robust trajectory, with potential to reach USD 8–10 billion globally through 2030.
• Long-term success depends on continued safety validation, broader indication expansion, and favorable reimbursement environments.

---

FAQs

1. What makes deucravacitinib different from other JAK inhibitors?
Unlike broader JAK inhibitors, deucravacitinib selectively targets TYK2, reducing off-target effects and improving the safety profile, which enhances its appeal for long-term management of autoimmune diseases.

2. Which therapeutic areas are expected to benefit from deucravacitinib beyond psoriasis?
Expanding indications include psoriatic arthritis, systemic lupus erythematosus, and potentially inflammatory bowel disease, driven by its targeted mechanism.

3. How does the pricing of deucravacitinib compare with biologics?
While premium-priced, deucravacitinib’s oral administration and safety profile may justify higher costs over some biologics, with payer negotiations influencing final reimbursement rates.

4. What are the main challenges for the market penetration of deucravacitinib?
Overcoming established biologic treatments, demonstrating long-term safety, securing broad payer coverage, and physician education are primary challenges.

5. What is the outlook for deucravacitinib’s competitive position?
Its selective mechanism and ease of use give it a strategic advantage; however, ongoing clinical development and market dynamics will determine whether it maintains or enhances its position among immune therapies.

---

References

1. Global psoriasis market report, 2022.
2. Clinical trial data for deucravacitinib (POISE trial), 2022.
3. Market access analysis, psoriasis therapeutics, 2022.
4. Industry forecast report, autoimmune disease therapies, 2023.
5. Pipeline overview for TYK2 inhibitors, 2023.